Nonvenereal Syphilis Treatment Market Size

  • Report ID: 3569
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Nonvenereal Syphilis Treatment Market Size

Nonvenereal Syphilis Treatment Market size was over USD 304.92 Million in 2023 and is expected to reach USD 923.74 Million by the end of 2036, growing at around 8.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of nonvenereal syphilis treatment is assessed at USD 329.34 Million. The growth of the market can be attributed to the improving coverage and accuracy of nonvenereal syphilis testing worldwide as well as the development of a novel rapid, point-of-care test (POCT) for confirmatory testing of active syphilis infection with the rising concern about the globally increasing transmission of bejel, especially among children living in tropical, subtropical, or warm arid climates, predominantly by direct contact. As per the World Health Organization data, more than 80,000 cases of bejel are reported every year worldwide.

Nonvenereal syphilis is an infectious disease common in some parts but rare in many parts of the world. The bejel infection is very similar to syphilis but its means of transmission typically comprises non-sexual skin contact or the common use of eating and drinking utensils against that of syphilis that is sexually transmitted. Concern about the spreading spiral bacteria of the genus Treponema has led to the increasing effort taken by governments as well as healthcare professionals worldwide to develop accurate diagnostic tools for the identification of infections caused by T. pallidum subspecies so that their treatments can be developed accordingly, which is expected to bring in revenue boost for the key market players in the nonvenereal syphilis treatment market. 


Nonvenereal Syphilis Treatment Market Overview
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3569
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of nonvenereal syphilis treatment is assessed at USD 329.34 Million.

The nonvenereal syphilis treatment market size was over USD 304.92 Million in 2023 and is expected to reach USD 923.74 Million by the end of 2036, growing at around 8.9% CAGR during the forecast period i.e., between 2024-2036. The rising cases of bejel as well as the increasing augmentation of infectious diseases are the major growth factors driving the growth of the market.

Middle East and Africa is likely to dominate majority industry share by 2036, attributed to existence of nonvenereal syphilis in regions of West Africa, the Mediterranean, and the Sahara propelled by lack of sanitization as well as the hot and humid climate.

Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample